PainChek (ASX:PCK) said a meeting with the US Food and Drug Administration (FDA) is scheduled this month to discuss its request for de novo regulatory clearance for the PainChek Adult App, according to a Wednesday filing with the Australian bourse.
The clearance would enable the company to enter the US healthcare market, potentially generating roughly $100 million per annum in aged care, the filing said.
Meanwhile, the company launched its PainChek Infant app on the Apple App Store, now available in Australia, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.